News | August 18, 2010

AHA Says Cardiac Computed Tomography is Safe, Accurate, Cost-Effective


August 18, 2010 - Cardiac computed tomography (CT) was found to be safe, accurate, and cost-effective in low risk patients in a recent scientific statement published by the American Heart Association (AHA), titled “Testing of Low-Risk Patients Presenting to the Emergency Department With Chest Pain.”

The paper summarizes the use of cardiac CT angiography as “Computed tomography coronary angiography has also shown promise in this setting. A negative accelerated diagnostic protocol evaluation allows discharge, whereas patients with positive findings are admitted. This approach has been found to be safe, accurate, and cost-effective in low-risk patients presenting with chest pain.”

The use of CT angiography is rapidly expanding, primarily due to well-published studies demonstrating cost effectiveness and safety in this population. Hospitals and cardiologists are increasingly turning to this test to determine who of those presenting to the emergency room can be safely discharged from the hospital in a timely fashion.

New, large randomized studies that were already presented, but not yet published, further reinforce the utility of this modality and the safety, efficacy and cost savings compared to other imaging tests.

These guidelines, in association with NICE guidelines recently published on the same topic, reiterate the important and growing role of cardiac CT angiography and calcium scoring as rapid methods to triage patients in the emergency department safely and most cost-effectively than other imaging modalities," said Matthew J. Budoff, M.D., FSCCT, professor of medicine at the David Geffen School of Medicine at UCLA, director of cardiac CT at Los Angeles Biomedical Research Center at Harbor UCLA Medical Center in Torrance, CA and president of the Society of Cardiovascular Computed Tomography (SCCT).

For more information: www.SCCT.org


Related Content

News | Cardiovascular Clinical Studies

Nov. 10, 2025 —Genomics, a science-led techbio company, has today announced new research that suggests polygenic risk ...

Home November 12, 2025
Home
News | Cardiovascular Clinical Studies

Oct. 21, 2025 – AskBio Inc., a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG ...

Home October 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 25, 2025 — Merck, known as MSD outside of the United States and Canada, has announced that new clinical trial and ...

Home August 25, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 18, 2025 — (Newswise) It’s often mistaken for a heart attack, but Takotsubo cardiomyopathy — previously known as ...

Home August 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 20, 2025 — A major international study published in Atherosclerosis* has found that routinely testing for ...

Home August 20, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 4, 2025 — Marea Therapeutics, Inc., a clinical-stage biotechnology company that develops next-generation medicines ...

Home August 04, 2025
Home
News | Cardiovascular Clinical Studies

July 16, 2025 — Medtronic has announced that the first patient has been enrolled in the PEripheral Onyx Liquid Embolic ...

Home July 22, 2025
Home
News | Cardiovascular Clinical Studies

June 11, 2025 — Bayer and the Broad Institute have have extended their research collaboration of 10 years by an ...

Home June 11, 2025
Home
News | Cardiovascular Clinical Studies

May 27, 2025 — Despite scientific advances in cardiovascular care, people in living in rural areas and other communities ...

Home May 27, 2025
Home
News | Cardiovascular Clinical Studies

May 20, 2025 — Shockwave Medical, Inc., part of Johnson & Johnson MedTechhas announced the 30-day primary endpoint ...

Home May 21, 2025
Home
Subscribe Now